Perry C Siatis sold $4.4M of ABBV
EVP, GC AND SECRETARY at AbbVie Inc.. 18,668 shares at an average of $234.39, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- +25Trade size$4.4M at market
- +20Share of holdings soldSold 80% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.7%, 3m -7.1%, 6m +12.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001951400-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | FTax withholding Common Stock, $0.01 par value10b5-1 | -14,850 | $232.08 | $3.4M | 23,287 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock, $0.01 par value10b5-1 | -5,777 | $233.51 | $1.3M | 17,510 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock, $0.01 par value10b5-1 | -10,291 | $234.66 | $2.4M | 7,219 | Mar 3, 2026 |
| Mar 2, 2026 | SOpen-market sale Common Stock, $0.01 par value10b5-1 | -2,600 | $235.26 | $612k | 4,619 | Mar 3, 2026 |
Related signals
Other insiders at AbbVie Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | ABBVsell AbbVie Inc. | Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | $8.2M 32,710 shares | -31% | |
| 68Notable | AbbVie Inc. | David Ryan Purdue SVP, Controller | $1.2M 5,230 shares | -66% | |
| 23Weak | AbbVie Inc. | Perry C Siatis EVP, GC AND SECRETARY | $5.1M 22,381 shares | -37% | |
| 43Moderate | AbbVie Inc. | Azita Saleki-Gerhardt EVP, CHIEF OPERATIONS OFFICER | $8.4M 42,370 shares | -19% | |
| 53Moderate | AbbVie Inc. | Nicholas Donoghoe EVP, CHIEF BUS/STRAT OFFICER | $2.6M 13,295 shares | -19% | |
| 45Moderate | ABBVsell AbbVie Inc. | Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER | $12M 58,832 shares | -52% | |
| 82Strong | AbbVie Inc. | Scott T Reents EVP, CHIEF FINANCIAL OFFICER | $3.7M 17,644 shares | -60% | |
| 40Moderate | AbbVie Inc. | Perry C Siatis EVP, GC AND SECRETARY | $5.8M 27,900 shares | -192% | |
| 60Notable | AbbVie Inc. | Richard A Gonzalez EXECUTIVE CHAIRMAN OF BOARD | $20M 98,628 shares | -20% | |
| 55Moderate | AbbVie Inc. | Timothy J. Richmond EVP, CHIEF HR OFFICER | $4.5M 21,250 shares | -78% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.